Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF
Authors' conclusion
The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation.
Study context
- Population
- Adults with newly diagnosed non-valvular AF (non-valvular atrial fibrillation (NVAF))
- Participants
- 17,162 adults
- Outcome
- All-cause mortality, stroke/systemic embolism and major bleeding
- Follow-up
- 2 years
Methodological detailsglobal, ongoing, Baseline: mean age 69.8 (SD 11.4) years; 43.8% women; mean CHA2DS2-VASc 3.3 (1.6), Therapy: 60.8% anticoagulant ± antiplatelet, 27.4% antiplatelet monotherapy, 11.8% no antithrombotic therapy
- Global
- Ongoing
- Baseline: mean age 69.8 (SD 11.4) years; 43.8% women; mean CHA2DS2-VASc 3.3 (1.6)
- Therapy: 60.8% anticoagulant ± antiplatelet, 27.4% antiplatelet monotherapy, 11.8% no antithrombotic therapy
Main finding
As reported in the abstract
Event rates per 100 person-years · 2-year follow-up
All-cause mortality, per 100 person-years
3.83
95% CI 3.62; 4.05
Stroke/SE, per 100 person-years
1.25
95% CI 1.13; 1.38
Major bleeding, per 100 person-years
0.70
95% CI 0.62; 0.81
Observational data: associations, not effects.
Further findings
Causes of death
- HF, ACS, sudden/unwitnessed death, malignancy, respiratory failure and infection/sepsis: share of known causes of death
- 65%
- Strokes: share of known causes of death
- <10%
Death with anticoagulant treatment
- Anticoagulant treatment associated with lower risk of death
- 35%
Original publication
Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J. Published 29 June 2016. doi:10.
Summarised from the published abstract; every number is checked against it